Jackson Lab, Wuhan Frasergen Bioinformatics to Launch Tumor Research Facility in China | GenomeWeb
Home » Jackson Lab, Wuhan Frasergen Bioinformatics to Launch Tumor Research Facility in China

Jackson Lab, Wuhan Frasergen Bioinformatics to Launch Tumor Research Facility in China

Jun 09, 2014
|
a GenomeWeb staff reporter

NEW YORK (GenomeWeb) – The Jackson Laboratory and Wuhan Frasergen Bioinformatics will create a cancer genomics research facility in China with the aim of developing new personalized treatments.

Under a memorandum of understanding, the companies plan to launch a facility in Wuhan, Hubei Province, which hosts a center for the Chinese Academy of Sciences, Jackson Lab said on Saturday.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Related Articles

Dec 22, 2015

Two-Child Policy Expected to Further Boost China's Growing NIPT Market

Premium
Aug 29, 2016

Jackson Laboratory to Launch Actionable Cancer Gene Panel as Clinical Dx Lab Grows

Premium
May 18, 2016

Q&A: Mao Mao, New Chief Scientific Officer of BGI Genomics, on Developing Clinical Genetic Tests

Premium
Sep 08, 2016

International Working Group Puts Forth Proposal for Improved Antibody Validation

Premium
Jan 14, 2016

20/20 GeneSystems Raises $4.5M in Series A Financing

May 13, 2016

Colorectal Cancer Patients' Cetuximab Response Can Be Discerned From FCGR2A Genotype

Premium

The Scan

This Week in PNAS

In PNAS this week: mutations linked to nasopharyngeal carcinoma, salivary proteins common among oral squamous cell carcinoma patients, and more.

Choice Against Testing

At Wired, a science journalist discusses her decision not to undergo BRCA testing.

Call for Gene Editing Oversight

The Japan Times says regulations are needed to oversee human genome-editing research.

This Week in PLOS

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.

What's Popular?

In Clinical & Translational

  1. MIT, Harvard Team Builds Nanosensor for Monitoring Cumulative Biomarker Exposure

  2. NCCN Mentions Prolaris, Oncotype DX in Updated Prostate Cancer Guidelines

  3. US Supreme Court Strikes Down Gene Patents but Allows Patenting of Synthetic DNA

  4. Ariosa's Harmony NIPT Gets CPT Code

  5. Genomic Health Study Highlights Discrepancy between Oncotype DX and MammaPrint Results

    Premium

Sponsorships

Privacy Policy.  Copyright © 2016 Genomeweb LLC.  All Rights Reserved.